

# 2024 Cumulative Antimicrobial Susceptibility Report



INPATIENT DATA

PeaceHealth St. John Medical Center

January 1 – December 31, 2024

Dash (-) = not tested, inappropriate, or < 30 strains tested. R = intrinsically resistant.

GRAM NEGATIVE ORGANISM  PERCENT SUSCEPTIBLE	# Isolates Tested	Beta-lactams										Fluoro-quinolones		Aminoglycosides			Miscellaneous			
		Penicillins			Cephems						Carbapenems		Ciprofloxacin	Levofloxacin	Amikacin	Gentamicin	Tobramycin	Nitrofurantoin - urine only	Tetracycline	Trimethoprim/sulfamethoxazole
		Ampicillin	Amoxicillin/clavulanic acid	Piperacillin/tazobactam	Cefazolin	Ceftazidime	Ceftriaxone	Cefepime	Cefoxitin	Cefpodoxime	Ertapenem	Meropenem								
Enterobacter cloacae complex	56	R	R	-	R	-	-	95	R	-	93	99	95	95	100	100	100	39	96	93
Escherichia coli	979	63	90	98	90	97	94	98	95	91	100	100	83	79	100	95	95	98	82	84
Klebsiella oxytoca	46	R	93	91	-	-	93	100	98	-	100	100	96	98	-	98	98	-	95	96
Klebsiella pneumoniae	153	R	96	97	96	98	95	99	97	95	100	100	94	92	100	99	97	26	90	92
Proteus mirabilis	70	83	100	100	100	100	100	100	94	100	100	100	83	83	100	96	97	R	R	83
Pseudomonas aeruginosa	90	R	R	88	-	83	R	89	-	-	R	99	86	76	100	-	100	-	R	R

NOTE: Third generation cephalosporins and piperacillin/tazobactam are unreliable for systemic infections with AmpC producing organisms (*E. cloacae*, *K. aerogenes*, or *C. freundii*), regardless of susceptibility data, due to the development of induced resistance on treatment.

*Haemophilus influenzae* beta lactamase positive: 20.9% (n=43)

Note: It is recommended that susceptibility data only be reported when there are at least 30 clinical isolates in the data set.

This antibiogram was created in compliance with CLSI M39-A4 Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data; Approved Guideline, 4<sup>th</sup> Edition, January 2014.

# 2024 Cumulative Antimicrobial Susceptibility Report



INPATIENT DATA

PeaceHealth St. John Medical Center

January 1 – December 31, 2024

Dash (-) = not tested, inappropriate, or < 30 strains tested. R = intrinsically resistant.

GRAM POSITIVE ORGANISM	# Isolates Tested	Beta lactams					Fluoro-quinolones		Amino-glycosides		Miscellaneous								
		Penicillins/Cephalosporins					Ciprofloxacin	Levofloxacin	Gentamicin Synergy	Streptomycin Synergy	Clindamycin	Daptomycin	Erythromycin	Minocycline	Nitrofurantoin - urine only	Rifampin	Tetracycline	Trimethoprim/sulfamethoxazole	Vancomycin
		Penicillin	Oxacillin	Ampicillin	Cefazolin	Ceftriaxone													
PERCENT SUSCEPTIBLE																			
<i>Enterococcus faecalis</i>	174	-	-	99	R	R	-	-	81	92	R	-	-	-	100	-	-	R	99
<i>Staphylococcus aureus</i> , MRSA	215	-	0	-	0	-	-	-	-	-	90	-	-	100	-	-	60	100	100
<i>Staphylococcus aureus</i> , MSSA	223	-	100	-	100	-	-	-	-	-	89	-	-	100	-	-	87	100	-
<i>Staphylococcus epidermidis</i>	31	-	32	-	32	-	-	-	-	-	-	-	-	-	-	-	-	-	100
<i>Streptococcus agalactiae</i> (Group B)	44	100	-	-	100	100	-	-	-	-	52	-	44	-	-	-	-	-	100
<i>Streptococcus anginosus</i>	41	100	-	-	-	100	-	-	-	-	-	-	-	-	-	-	-	-	100
<i>Streptococcus pneumoniae</i>	74	100*	-	-	-	100*	-	100	-	-	-	-	-	-	-	-	-	-	-
<i>Streptococcus pyogenes</i> (Group A)	73	100	-	-	100	100	-	-	-	-	72	-	72	-	-	-	-	-	100

\*Non-meningitis breakpoint

Note: It is recommended that susceptibility data only be reported when there are at least 30 clinical isolates in the data set.

This antibiogram was created in compliance with CLSI M39-A4 Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data; Approved Guideline, 4<sup>th</sup> Edition, January 2014.